ONCE-WEEKLY BASAL INSULIN FC (BIF) DEMONSTRATED SIMILAR GLYCEMIC CONTROL TO ONCE-DAILY INSULIN DEGLUDEC (DEG) IN INSULIN-NAIVE PATIENTS WITH TYPE 2 DIABETES (T2D)

被引：0
|
作者：
Bue-Valleskey, J. [1 ]
Kazda, C. [1 ]
Ma, C. [1 ]
Chien, J. [1 ]
Zhang, Q. [1 ]
Chigutsa, E. [1 ]
Landschulz, W. [1 ]
Swan, J. [1 ]
Haupt, A. [1 ]
Frias, J. P. [2 ]
机构：
[1] Eli Lilly & Co, Global Sci Commun, Indianapolis, IN USA
[2] Veloc Clin Res, Los Angeles, CA USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
620
引用
收藏
页码：A193 / A193
页数：1
相关论文
共 50 条
  • [31] Cost-utility analysis of once-weekly insulin icodec and once-daily insulin glargine in patients with type 2 diabetes receiving basal-bolus insulin therapy in China
    Dai, Nan
    Su, Xiaorong
    Wang, Yong
    DIABETES OBESITY & METABOLISM, 2025, 27 (01): : 377 - 386
  • [32] ONCE WEEKLY BASAL INSULIN FC (BIF): AN UPDATE ON THE TYPE 2 DIABETES CLINICAL DEVELOPMENT PROGRAM
    Frias, J. P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A13 - A13
  • [33] Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by ethnicity and race: ONWARDS 1-5
    Lingvay, I.
    Bangsgaard, K. O.
    Desouza, C.
    Fragao-Marques, M.
    Navarria, A.
    Vianna, A.
    DIABETOLOGIA, 2024, 67 : S375 - S376
  • [34] Similar Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin Naive or Experienced Patients with T2D
    Silver, Robert J.
    Asong, Marisse
    Begtrup, Kamilla
    Koefoed, Mette M.
    Heller, Simon R.
    Rosenstock, Julio
    DIABETES, 2021, 70
  • [35] Hypoglycemia Frequency and Physiological Response to Double or Triple Doses of Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine in T2D
    Svehlikova, Eva
    Arfelt, Kristine Niss
    Cailleteau, Roman
    Deller, Sigrid
    Thomsen, Karen Margrete
    Hart, Marlies
    Mursic, Ines
    Pieber, Thomas
    Haahr, Hanne
    DIABETES, 2022, 71
  • [36] Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
    Bajaj, Harpreet S.
    Bergenstal, Richard M.
    Christoffersen, Andreas
    Davies, Melanie J.
    Gowda, Amoolya
    Isendahl, Joakim
    Lingvay, Ildiko
    Senior, Peter A.
    Silver, Robert J.
    Trevisan, Roberto
    Rosenstock, Julio
    DIABETES CARE, 2021, 44 (07) : 1586 - 1594
  • [37] A novel once weekly basal insulin Fc achieved similar glycaemic control with a comparable safety profile versus insulin degludec in patients with type 1 diabetes
    Kazda, C.
    Bue-Valleskey, J.
    Chien, J.
    Zhang, Q.
    Chigutsa, E.
    Landschulz, W.
    Wullenweber, P.
    Haupt, A.
    Dahl, D.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S329 - S329
  • [38] Once weekly basal insulin Fc is safe and efficacious in patients with type 2 diabetes previously treated with basal insulin
    Frias, J.
    Chien, J.
    Zhang, Q.
    Chigutsa, E.
    Landschulz, W.
    Wullenweber, P.
    Haupt, A.
    Kazda, C.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 72 - 72
  • [39] CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naive T2D-ONWARDS 1 Exploratory Analysis
    Bergenstal, Richard M.
    Watt, Sara K.
    Matos, Ana Laura S. A.
    Lingvay, Ildiko
    Mader, Julia K.
    Nishida, Tomoyuki
    Rosenstock, Julio
    DIABETES, 2023, 72
  • [40] Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in individuals with type 2 diabetes by kidney function: ONWARDS 1-5
    Cheng, A. Y. Y.
    Rossing, P.
    Benamar, M.
    Laugesen, C.
    Nielsen, P. H.
    Bajaj, H. S.
    DIABETOLOGIA, 2024, 67 : S375 - S375
12345